Cannabinoids as hippocampal network administrators.
Author: Lupica CR1, Hu Y2, Devinsky O3, Hoffman AF4
Affiliation:
1U.S. Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse Intramural Research Program, Electrophysiology Research Section, Baltimore, MD, USA. Electronic address: clupica@mail.nih.gov.
2School of Chemistry, Food and Nutritional Sciences and Pharmacy, University of Reading, Reading, UK.
3Dept of Neurology, NYU School of Medicine, USA.
4U.S. Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse Intramural Research Program, Electrophysiology Research Section, Baltimore, MD, USA.
Conference/Journal: Neuropharmacology.
Date published: 2017 Apr 6
Other:
Pages: S0028-3908(17)30140-5 , Special Notes: doi: 10.1016/j.neuropharm.2017.04.003. [Epub ahead of print] , Word Count: 213
Extensive pioneering studies performed in the hippocampus have greatly contributed to our knowledge of an endogenous cannabinoid system comprised of the molecular machinery necessary to process these endocannabinoid lipid messengers and their associated cannabinoid receptors. Moreover, a foundation of knowledge regarding the function of hippocampal circuits, and its role in supporting synaptic plasticity has facilitated our understanding of the roles cannabinoids play in the diverse behaviors in which the hippocampus participates in both normal and pathological states. In this review, we present an historical overview of research pertaining to the hippocampal cannabinoid system to provide context in which to understand the participation of the hippocampus in cognition, behavior, and epilepsy. We also examine potential roles for the hippocampal formation in mediating dysfunctional behavior, and assert that these phenomena reflect disordered physiological activity within the hippocampus and its interactions with other brain regions after exposure to synthetic cannabinoids, and the phytocannabinoids found in marijuana, such as Δ9-THC and cannabidiol. In this regard, we examine contemporary hypotheses concerning the hippocampal endocannabinoid system's participation in psychotic disorders, schizophrenia, and epilepsy, and examine cannabinoid-sensitive cellular mechanisms contributing to coherent network oscillations as a potential contributor to these disorders.
Copyright © 2017. Published by Elsevier Ltd.
KEYWORDS: Cannabinoid CB(2) receptors; Cholecystokinin; GABA; Gamma oscillation; Neuroregulin; Parvalbumin
PMID: 28392266 DOI: 10.1016/j.neuropharm.2017.04.003
BACK
